Herzuma launch?

Are you asking about the launch date of Herzuma (the trastuzumab biosimilar) in a specific country or region? If you tell me the country/market, I can give you the exact launch date and current regulatory status.

Here’s a quick overview in case it helps:
- What it is: Herzuma is a biosimilar to trastuzumab, used for HER2-positive cancers (e.g., metastatic breast cancer, early breast cancer, and certain gastric/GEJ cancers). It’s designed to have similar efficacy and safety to the reference product.
- Indications and use: Typically used in combination with chemotherapy regimens as per the trastuzumab labeling.
- Regulatory status: Approval timelines for Herzuma vary by country. Biosimilars often undergo approval processes with the EMA, FDA, and other regulators, and launch dates depend on market approvals, pricing, and reimbursement decisions.

If you share the country or region you care about (e.g., EU, US, UK, a specific country in Asia or Latin America), I’ll look up the exact launch date and current status.